Literature DB >> 11089900

Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation.

G Chinetti1, J C Fruchart, B Staels.   

Abstract

Peroxisome proliferator-activated (PPARs) are ligand-activated transcription factors belonging to the nuclear receptor family. PPARs function as regulators of lipid and lipoprotein metabolism and glucose homeostasis and influence cellular proliferation, differentiation and apoptosis. PPARalpha is highly expressed in tissues such as liver, muscle, kidney and heart, where it stimulates the beta-oxidative degradation of fatty acids. PPARgamma is predominantly expressed in intestine and adipose tissue. PPARgamma triggers adipocyte differentiation and promotes lipid storage. The hypolipidemic fibrates and the antidiabetic glitazones are synthetic ligands for PPARalpha and PPARgamma, respectively. Furthermore, fatty acids and eicosanoids are natural PPAR ligands: PPARalpha is activated by leukotriene B4, whereas prostaglandin J2 is a PPARgamma ligand. These observations suggested a potential role for PPARs not only in metabolic but also in inflammation control. The first evidence for a role of PPARalpha in inflammation control came from the demonstration that PPARalpha deficient mice display a prolonged response to inflammatory stimuli. It was suggested that PPARalpha deficiency results in a reduced beta-oxidative degradation of these inflammatory fatty acid derivatives. More recently, PPAR activators were shown to inhibit the activation of inflammatory response genes (such as IL-2, IL-6, IL-8, TNFalpha and metalloproteases) by negatively interfering with the NF- kappaB, STAT and AP-1 signalling pathways. PPAR activators exert these anti-inflammatory activities in different immunological and vascular wall cell types such as monocyte/macrophages, endothelial, epithelial and smooth muscle cells in which PPARs are expressed. These recent findings indicate a modulatory role for PPARs in the control of the inflammatory response with potential therapeutic applications in inflammation-related diseases, such as atherosclerosis and inflammatory bowel disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11089900     DOI: 10.1007/s000110050622

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  238 in total

Review 1.  Small therapeutic molecules for the treatment of inflammatory bowel disease.

Authors:  S J H van Deventer
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

Review 2.  Transcriptional regulation of hepatic stellate cell activation.

Authors:  D A Mann; D E Smart
Journal:  Gut       Date:  2002-06       Impact factor: 23.059

3.  Peroxisome proliferator activated receptor-γ and traumatic brain injury.

Authors:  Lei Qi; Asha Jacob; Ping Wang; Rongqian Wu
Journal:  Int J Clin Exp Med       Date:  2010-09-23

Review 4.  The Deleterious Effects of Oxidative and Nitrosative Stress on Palmitoylation, Membrane Lipid Rafts and Lipid-Based Cellular Signalling: New Drug Targets in Neuroimmune Disorders.

Authors:  Gerwyn Morris; Ken Walder; Basant K Puri; Michael Berk; Michael Maes
Journal:  Mol Neurobiol       Date:  2015-08-27       Impact factor: 5.590

5.  4',6-Dimethoxyisoflavone-7-O-β-D-glucopyranoside (wistin) is a peroxisome proliferator-activated receptor α (PPARα) agonist in mouse hepatocytes.

Authors:  Misato Suzuki; Fumiya Nakamura; Emi Taguchi; Maho Nakata; Fumi Wada; Momoka Takihi; Tomoyo Inoue; Shinji Ohta; Hiroyuki Kawachi
Journal:  Mol Cell Biochem       Date:  2018-01-09       Impact factor: 3.396

6.  Liver receptor homolog 1 is a negative regulator of the hepatic acute-phase response.

Authors:  Nicolas Venteclef; Jason C Smith; Bryan Goodwin; Philippe Delerive
Journal:  Mol Cell Biol       Date:  2006-09       Impact factor: 4.272

7.  Creeping fat in Crohn's disease: travelling in a creeper lane of research?

Authors:  A Schäffler; H Herfarth
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

8.  9-Oxo-10(E),12(Z),15(Z)-Octadecatrienoic Acid Activates Peroxisome Proliferator-Activated Receptor α in Hepatocytes.

Authors:  Haruya Takahashi; Kosuke Kamakari; Tsuyoshi Goto; Hideyuki Hara; Shinsuke Mohri; Hideyuki Suzuki; Daisuke Shibata; Rieko Nakata; Hiroyasu Inoue; Nobuyuki Takahashi; Teruo Kawada
Journal:  Lipids       Date:  2015-09-19       Impact factor: 1.880

Review 9.  Role of inflammatory pathways in the development and cardiovascular complications of type 2 diabetes.

Authors:  Milagros G Huerta; Jerry L Nadler
Journal:  Curr Diab Rep       Date:  2002-10       Impact factor: 4.810

10.  Pilot study investigating the ability of an herbal composite to alleviate clinical signs of respiratory dysfunction in horses with recurrent airway obstruction.

Authors:  Wendy Pearson; Armen Charch; Dyanne Brewer; Andrew F Clarke
Journal:  Can J Vet Res       Date:  2007-04       Impact factor: 1.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.